Risk factor
Considerable default risk
Profitability factor
Greatly overvalued vs peers
About
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of BPMC is 130 and suggests 0% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation su
Buy
Sell